FDA Approves Siemens Mobilett Mira Mobile Digital X-Ray System
Siemens Healthcare’s Mobilett Mira, the company’s first mobile digital X-ray system with a wireless detector, has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available in the United States.
Siemens Healthcare’s Mobilett Mira, the company’s first mobile digital X-ray system with a wireless detector, has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available in the United States.
The Mobilett Mira’s wireless capacity helps with examinations of patients with limited mobility, and its rotating swivel arm helps increase ease-of-use for clinical staff, the company said.
Similar to their mobile X-ray systems, the device has a rotating swivel arm so that, rather than moving the patient around, radiologists and technologists can move the swivel arm instead. Siemens officials said, though, that theirs is the first mobile X-ray device using a wireless detector, which does away with the data cable needed with other such devices.
The Mobilett Mira has 7-megapixel resolution and exposure times shorter than 1 millisecond.
The X-ray swivel arm moves vertically and rotates 90 degrees, integrating electric connection cables. In addition, the company said, the Mobilett Mira is the first mobile X-ray system that can be maintained and updated via remote monitoring. Siemens Remote Services (SRS) regularly provides the system with recommended software updates.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
